Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. - Wikidata - wikimedia - TriplyDB

Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.

Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.

http://www.wikidata.org/entity/Q37373486

about

The Contribution of Advanced Glycation End product (AGE) accumulation to the decline in motor function Advanced glycated end-products affect HIF-transcriptional activity in renal cells Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure Skin autofluorescence and all-cause mortality in stage 3 CKD.Association of insulin-related serum factors with colorectal polyp number and type in adult males.Novel Inhibitory Effects of Glycyrrhizic Acid on the Accumulation of Advanced Glycation End Product and Its Receptor Expression.Novel insights into the relationship between diabetes and osteoporosis Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway.Low Bone Mass is Associated with Increased Carotid Intima Media Thickness in Men with Type 2 Diabetes Mellitus.Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study.Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus.Diabetes mellitus and osteoporosis.Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease.Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an in-vitro model of human proximal tubular epithelial cells.Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study Is Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.Perspectives on RAGE signaling and its role in cardiovascular disease.High plasma level of soluble RAGE is independently associated with a low recurrence of atrial fibrillation after catheter ablation in diabetic patient.Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease.Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.

P2860

Q26767495-0578E34E-C899-439A-BF09-F81E4D230243 Q28591845-D29B3469-D5D8-4714-B3CF-04505D705101 Q33810217-6912FEB3-031A-43C8-9435-BC7132E8E55B Q34008927-CB0F4378-140E-454C-B4B0-816CDD11C2D8 Q34135535-31BFA8F5-D8DC-45AE-9FC2-BA92969D6E91 Q34604583-80784C6C-3441-45CF-ACF0-35F68DAEB304 Q35674683-C573EC05-2786-4F53-B85B-827CFD6FEDA3 Q35837912-F7871611-BDE1-4A99-B517-16748B24C839 Q35882416-94628EB1-8770-4691-BDBE-FE33024E9399 Q35935760-D1AB0FA8-284D-425B-9BC1-94899CB20224 Q35985860-1CBFF41F-24B5-48F5-A029-2B4AC2E7985F Q36321887-85598B0A-7DDD-4D34-9DF8-4EBBDA422109 Q36929402-B2F4D5A1-94E3-4C89-A7B2-5D24D4511D02 Q37113344-9F898B2F-A605-4E9F-A8B2-86D673BB594D Q37235902-0E937443-BE33-401E-B8E7-C3E72B6B21DC Q37831838-1FD1BBC3-E7D6-4EDE-BC96-493C348A7702 Q38028344-8284900A-613E-4D99-8301-94493B0FBB8B Q38087556-A624F47B-6F99-467D-A4AF-5439052BF1C2 Q38370045-AC95A1D9-A246-49F3-BEB7-138C3000738F Q38651423-9B9524A6-DA4A-4B6E-8290-E28C5D37518C Q39027326-7EF98A39-F23A-4C33-B071-69599D5387FE Q39190228-A61270E0-786A-4302-AD51-77D2048FF679 Q41702511-DF729E68-E0CF-48BF-8C1C-AC462E08C92E Q41975172-705A03CD-38A5-4ED6-96F4-8F017DBD5FA2 Q51325589-E118CC49-17A0-4752-919E-CFC29A814EC1 Q53344878-B032A5E6-AF4D-420F-9460-446BD670659D Q53762692-5A536C0F-ECC8-44F9-82D3-ECAE2F956FD2 Q54605224-69C8E0AC-FE84-4DD5-8625-F9236E39630D Q55474587-EB85AC82-A86F-4099-BBF0-97467F616267

P2860

Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.

http://www.wikidata.org/entity/Q37373486

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Receptor for advanced glycatio ...... : cardiovascular implications.

@en

type

label

Receptor for advanced glycatio ...... : cardiovascular implications.

@en

prefLabel

Receptor for advanced glycatio ...... : cardiovascular implications.

@en

P1433

Q37373486-510CF5DC-E0A5-41C7-B5AA-9A31629233BB

P1476

Q37373486-282FF94B-14D6-4E38-83BF-DFB7DDE3F98E

P2093

Q37373486-2BFF637E-BFCB-404C-B39C-74650FC677BA

Q37373486-5142BD40-2931-4061-A2CB-2B7116A78474

Q37373486-6949F9C7-75F4-41C8-8643-884A1C17579F

P2860

Q37373486-0476F60D-7844-4594-8C36-0A131EA88C7E

Q37373486-057ECD91-BD08-451C-8699-4CDF2609D7B7

Q37373486-06FFD570-3145-43E7-B9DA-58BD11E4CD94

Q37373486-0AB7B591-6521-4560-AFA3-8DCA84386D05

Q37373486-0D86A448-A7E7-4C47-860E-A9B5C00F99A5

Q37373486-187655CF-A653-491C-B3C2-ECEC8759ABC6

Q37373486-1B4715B6-1072-413D-835C-BB8A8A328B02

Q37373486-221AC0B0-C8A7-4248-BC6A-2AD0026C55A9

Q37373486-2271E8AD-0CA5-4BF5-9B39-680048E044D7

Q37373486-22ED2890-F969-4DB9-A887-A1361C6703BF

P304

Q37373486-27295C9B-ECCC-4ECF-9174-5084B8A8543A

P31

Q37373486-18AF3084-814F-4677-8A31-BF6BDA8AE331

P356

Q37373486-0A55A57A-8E66-44D9-A620-421261CE7DF9

P407

Q37373486-9ADA7000-EE43-4DBA-A050-3E3B0EB58608

P433

Q37373486-32C66A18-4E66-467A-AD50-85CDC016D3B9

P478

Q37373486-FA5693E4-9CAA-45A1-B779-2EF4085552C8

P50

Q37373486-7C9D1F77-6767-4BDE-8031-B74505F06CB1

P577

Q37373486-A151280C-26B5-4163-A25C-6E27CD6052E7

P5875

Q37373486-04DBD59E-FF5D-479F-B72C-2D61E321601E

P698

Q37373486-B88FE956-A79B-46F1-AAC3-CF9376515FBD

P356

P1433

Diabetes and Vascular Disease Research

P1476

Receptor for advanced glycatio ...... ): cardiovascular implications

@en

P2093

Darren K McGuire

http://www.w3.org/2001/XMLSchema#string

Jason B Lindsey

http://www.w3.org/2001/XMLSchema#string

Shuaib M Abdullah

http://www.w3.org/2001/XMLSchema#string

P2860

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Alpha-glucosidase inhibitors for type 2 diabetes mellitus

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

P304

7-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3132/DVDR.2009.002

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Cipollone

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23804455

http://www.w3.org/2001/XMLSchema#string

P698

19156622

http://www.w3.org/2001/XMLSchema#string